Kornimate/medical-research-clean huggingface dataset:
quantification of antisense hiv rna in patients

Conditions: HIV-1-infection

Summary: the objective of this study is to quantify the expression levels of the hiv-1 unspliced sense transcript and of total hiv-1 antisense transcripts in pbmcs of hiv-1-infected persons, either still untreated or virologically controlled on treatment, and to investigate their correlations with the hiv reservoir as assessed by the quantification of total and integrated hiv-1 dna.

the research team will quantify the expression level of total hiv-1 antisense transcripts in pbmcs from two groups of hiv-1-infected persons: still untreated and virologically controllled on treatment. the research team will also study (i) the correlation between the expression level of total hiv-1 antisense transcripts and the levels of total and integrated hiv-1 dna in pbmcs, (ii) the correlation between the expression level of the unspliced hiv-1 sense transcript and the levels of total and integrated hiv-1 dna in pbmcs, (iii) the correlation between the expression levels of total hiv-1 antisense transcripts and the level of the unspliced hiv-1 sense transcript in pbmcs, (iv) whether the correlations are different in the two groups of hiv-1-infected persons : still untreated patients vs. patients with virological control on antiretroviral treatment. quantification of viral transcripts will rely on quantitative rt-pcrs, yielding the quantity of viral rnas, normalized on the expression of 2 housekeeping genes, and on a digital rt-pcr, yielding the absolute number of viral rna copies. the quantification of total and integrated hiv-1 dna will rely on a quantitative pcr yielding the number of hiv-1 dna copies/million of pbmcs, according to the technique described in tremeaux p et al, ebiomedicine 2019;41:455-64. the percentage of intact proviral dna will be estimated according to the technique described in bruner km et al, nature 2019; 566 :120-5

Eligibility criteria:
inclusion criteria: * hiv-1 infection * ability to understand the objectives and protocols of the research and to sign the informed consent \* group 1 : treatment-naive patients with a detectable hiv-1 viral load * have not received any antiretroviral treatment * at the chronic stage as determined during the clinical examination and confirmed by a western blot complete hiv antigens ("env" bands (gp 120 and 160). + "gag" and "pol" bands) with the presence of p31+ \*group 2: patients with chronic hiv-1 infection on antiretroviral therapy efficient * have been on antiretroviral therapy for less than a year * with a plasma hiv rna \< 50 copies/ml of blood for at least 6 months exclusion criteria: * ongoing hiv primary infection * coinfection with hiv-2 or htlv-1/2 * ongoing aids-defining clinical condition * ongoing infectious disease of any type * ongoing immunosuppressive treatment * incompetent adults, persons under the protection of a conservator, tutor or guardian * participation in a trial testing a medication in the 3 months preceding blood sampling * pregnant or lactating woman

Keywords: hiv-1
bilevel versus servoventilation in complex sleep apnea

Conditions: Complex Sleep Apnea; CPAP Induced Central Sleep Apnea

Summary: randomized trial to evaluate the performance of bilevel vs. servoventilation in patients with complex sleep apnea during continuous positive airway pressure (cpap) treatment.

patients with primary obstructive sleep apnea, who develop complex sleep apnea after cpap treatment of 4-6 weeks duration were randomized to either receive bilevel of servoventilation treatment. parameters of sleep as well as apnea-hypopnea indices are to be compared.

Eligibility criteria:
inclusion criteria: predominant obstructive apnea without treatment predominant central apnea with cpap treatment exclusion criteria: primary central sleep apnea non-compliance to cpap therapy

Keywords: sleep apnea central sleep apnea bilevel servoventilation cpap
evaluation of efficacy of musical treadmill in pd rehabilitation

Conditions: Parkinson Disease; Gait Disorders, Neurologic; Treadmill

Summary: in order to evaluate the effectiveness of musical treadimll on gait parameters in patients with parkinson's disease, the investigators compare the outcome measures on two group of patients: one will undergo a 4-week daily musical treadmill training and one will undergo a 4-week daily traditional treadmill training

gait is altered in parkinson's disease (pd) patients. it has been shown that treadmill training is useful in improving the gait's parameters in patients in early-moderate stages of disease. moreover, it has been shown that the music, exploiting the entrainment, is effective in order to ameliorate several gait parameters, as step lenghts and cadence. no data are available about the effectiveness of the association between treadmill and music. the aim of this study is to evaluate the effect of a gait training using musical treadmill in patients in stages i-ii-iii hoehn \& yahr (h\&y). 100 patients with pd in early-moderate stage of disease will be enrolled. all patients will undergo an intensive treatment: 2 session of 20-minutes treadmill training per day, 5 times a week, for 4 weeks. treadmill speed will be previously set at 20% less the confidence speed and progressively increased of 20%. all patients will be evaluat at the enrolment and at the end of the treatment. the outcome misures are: 6 minute walking test and timed up and go test.

Eligibility criteria:
inclusion criteria: * stage 2.5-3 according to the hoehn and yahr scale (h\&y); * stable pharmacological treatment for the last 6 weeks before the enrolment and during the hospitalization; * mini mental state examination (mmse) ≥ 24; exclusion criteria: * any focal brain lesion detected in brain imaging studies (ct or mri) performed in the previous 12 months; * drug-induced dyskinesias; * disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific items of updrs iii; * behavioral disturbances (evaluated with neuropsychiatric inventory); * visual and auditory dysfunctions according to the general clinical evaluation and medical history;
genetic linkage study of idiopathic talipes equinovarus (itev) (clubfoot)

Conditions: Clubfoot

Summary: the goal of this study is to identify and characterize the genetic loci causing idiopathic talipes equinovarus (clubfoot). the hypothesis is that a few genes account for a substantial fraction of itev and that these genes can be identified in defined populations. towards this goal, in preliminary studies, dr. hecht's group has identified two genes, nat2 and casp10, which demonstrate evidence for linkage and association to itev.

blood collection: for this study, the investigators need to obtain blood samples from members of families in which clubfoot has occurred; more specifically, blood samples from the affected child and both parents. dna will be extracted from blood samples. the dna will then be tested to look for genetic factors that cause clubfoot. study questionnaires: as well as the blood samples, the investigators have a short questionnaire for the mother of the child with clubfoot to complete.

Eligibility criteria:
inclusion criteria: * one family member, usually child, must have clubfoot

Keywords: genetics clubfoot dna idiopathic talipes equinovarus also known as clubfoot
raltegravir in the swiss hiv cohort study

Conditions: HIV Infection

Summary: since june 2007, raltegravir has been available in switzerland within a named patient program for patients who have virologic failure, triple class experience and resistance, and no other treatment options. this proposal has been designed to evaluate efficacy and safety data among patients who receive raltegravir within the routine clinical practice in switzerland and who participate in the swiss hiv cohort study. this is a combined retrospective analysis of patients who already received raltegravir and a prospective part of patients who enter the named patient program and will be followed up in a standardized way. in the prospective part, patients will also be able to receive raltegravir in case of intolerance to their current medication with virologic suppression. the analysis will primarily use descriptive statistics. in addition, we will assess the duration of virologic response and focus on predictors of hiv rna suppression during a follow-up of at least 6 months. in the prospective part, we will assess trough plasma levels of raltegravir and other antiretrovirals. in patients who will develop virologic failure, genotypic and phenotypic resistance to raltegravir (and other antiretrovirals) will be performed to characterize the evolution of resistance during the raltegravir-containing regimen.


Eligibility criteria:
inclusion criteria: * all patients treated with raltegravir within the swiss hiv cohort study exclusion criteria: * drop out of the swiss hiv cohort study

Keywords: hiv antiretroviral treatment swiss hiv cohort study drug resistance integrase inhibitor treatment
agili-ctm implant performance evaluation in the treatment of osteoarthritis of the great toe

Conditions: Osteoarthritis of Multiple Joints of Ankle or Foot

Summary: the purpose of this study is to evaluate the performance of the agili-ctm implant in the treatment of osteoarthritis of the great toe.

agili-c™ implant is a ce marked. the agili-ctm implant is a porous resorbable tissue regeneration scaffold for the treatment of articular cartilage and/or osteochondral defects. the agili-c™ implant will be implanted using the agili-kit™ surgical toolset which is designed for the precise preparation of sites in cartilage and osteochondral defects, for implanting the agili-c™ implant.

Eligibility criteria:
inclusion criteria: * 18 years or older * osteoarthritis of the first metatarsophalangeal joint * presence of good bone stock * physically and mentally willing and able to comply with post-operative * rehabilitation and routinely scheduled clinical and radiographic visits exclusion criteria: * \< 18 years of age * any past or present evidence of infection of the treated joint * any known malignant tumor of the foot * known inflammatory arthropathy or crystal-deposition arthropathy * chemotherapy treatment in the past 12 months * history of allergic reaction or intolerance to calcium carbonate or hyaluronate * patient who is pregnant or intends to become pregnant during the study * history of any significant systemic disease, such as but not limited to, hiv infection, hepatitis infection or htlv infection; known coagulopathies, that might compromise the subject's welfare * known substance abuse or alcohol abuse * participation in other clinical trials in parallel to this study * known insulin dependent diabetes mellitus * unable to undergo imaging studies
role of ctc´s spread during pancreaticoduodenectomy in patients with pancreatic and periampullary tumors

Conditions: Pancreatic Tumor; Periampullary Carcinoma Resectable; Circulating Tumor Cells; Metastasis

Summary: this multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (ctcs) during cephalic duodenopancreatectomy in patients with pancreatic and periampullary tumors.

cephalic duodenopancreatectomy is the technique indicated for patients with pancreatic head carcinoma and periampullar tumors. there are different technical variants, it is not standardized what is the best option in relation to local recurrence, metastasis and survival. in the study, patients will be randomized into two study groups with pancreatic and periampullary tumors undergoing cephalic pancreatectomy (nt) vs initial approach by superior mesenteric artery (sma). the measurement of circulating tumor cells (ctcs) allows to assess the degree of cellular dissemination due to surgical manipulation.ctcs will be evaluated during surgery (nº ctcs / ml blood). to do this, a maximum of 4 blood samples from the portal vein will be performed, in each study group according to the following scheme: * nt group: basal (at the beginning of surgery), portal vein pancreatic detachment, postresection (nt2) and before closure (nt3). * sma group: basal (at the beginning of surgery), after kocher maneuver and sma dissection, postresection, before closure. subsequently, the quantified levels of ctcs will be correlated with the occurrence of local tumor recurrence, metastasis development and patient patient survival.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years, with adenocarcinomas of the pancreas and potentially resectable periampullary tumors by cephalic duodenopancreatectomy or total duodenopancreatectomy indicated intraoperatively for technical reasons, who voluntarily agree to participate in the study and sign informed consent exclusion criteria: 1. patients in whom liver metastases or peritoneal carcinomatosis are detected during surgery. 2. patients with neuroendocrine pancreatic tumors or cystic tumors. 3. patients in whom tumor resection is not finally achieved because it shows intraoperatively that the tumor is locally advanced and unresectable. 4. patients with macroscopic residual tumor (r2). 5. high-risk patients with severe pathology (asa iv) according to the american association of anesthesiologists. 6. patients receiving neoadjuvant therapy 7. patients in whom the intraoperative pathological anatomy indicates borders of pancreatic resection affected
efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in japan. the aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in subjects with insulin requiring diabetes.


Eligibility criteria:
inclusion criteria: * duration of diabetes mellitus for at least 2 years * current treatment of basal-bolus regimen for at least 12 weeks using an intermediate/long-acting human insulin and insulin aspart * hba1c below 11.0% exclusion criteria: * impaired renal function * impaired hepatic function * serious heart diseases * known hypoglycaemia unawareness or recurrent major hypoglycaemia * proliferative retinopathy or maculopathy requiring acute treatment * uncontrolled treated/untreated hypertension * current treatment with total insulin dose of more than 100 iu/day * current treatment or expected at the screening to start treatment with systemic corticosteroids
effects of control scan for presumed difficult epidural infiltrations (echorachis)

Conditions: Sciatica

Summary: the aim of this care protocol is to study the effects of scan to help epidural infiltration realization, in presumed difficult patients suffering from sciatica. these scans are already performed in our rheumatology department but our objective is to evaluate objectively its contribution for patients and doctors. epidural infiltration in young patients, with an easy anatomical identification, causes generally no technical difficulties, therefore this protocol will only include patients presumed to have a difficult infiltration, that means those aged more than 60, and/or with bmi \> 30 and/or suffering from scoliosis. this study concerns patients who are hospitalized in rheumatology department (hospital of nantes) for their first epidural infiltration for treatment-resistant lombosciatica. patient will be randomized at day 0, before infiltration. this latter will be performed in accordance to current practice. tolerance data (pain and satisfaction) will be collected just after the infiltration and eventual complications will be reported within 48 hours after infiltration. following treatment of lombosciatic will be realized through hospitalization, as usual. scan is a safe, non invasive, painless and non radiating exam. it is the extension of the musculoskeletal clinical exam and it has already changed our rheumatology practices. the investigators hope at the end of this study, that results would confirm that scan can be a help in practice to perform epidural infiltrations.


Eligibility criteria:
inclusion criteria: * major patients hospitalized in rheumatology department for performing their first epidural infiltration when sciatica is resistant to medical treatment. * inclusion of patients older than 60 years and / or bmi superior to 30 and / or scoliosis exclusion criteria: * refusal to participate * history of spinal surgery * anticoagulant or antiplatelet * history of spinal malformations type spina bifida * pregnancy * age\<18 * patients under guardianship * patients participating to another clinical trial (except non interventional trials) * patients unable to achieve the protocol, in the judgment of the investigator

Keywords: scan control epidural infiltration visual analogue scale (vas)
bone marrow transplantation in treating patients with chronic lymphocytic leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. purpose: phase ii trial to study the effectiveness of bone marrow transplantation in treating patients with chronic lymphocytic leukemia.

objectives: examine the potential role for high dose cyclophosphamide, total body irradiation and bone marrow transplantation for patients with chronic lymphocytic leukemia who are at high risk for disease progression. outline: patients receive daily intravenous infusions of cyclophosphamide for two days, followed by total body irradiation in four daily exposures. after completion of the total body irradiation, allogeneic or autologous bone marrow is infused intravenously. projected accrual: 50 patients are expected to be accrued.

Eligibility criteria:
disease characteristics: chronic lymphocytic leukemia (cll) patients after initial relapse who have achieved a complete or partial remission with fludarabine therapy or after initial relapse or progression prolymphocytic leukemia in first remission or after relapse patients 15-65 years old who lack an hla-identical sibling are eligible for autologous bm transplantation patients 16-50 years old with an hla identical or one antigen mismatched related donor are eligible for allogeneic bm transplantation patient characteristics: age: 15-65 (see disease characteristics) performance status: zubrod no more than 2 hematopoietic: not specified hepatic: bilirubin no greater than 1.5 mg/dl renal: creatinine no greater than 1.5 mg/dl cardiovascular: cardiac ejection fraction at least 50% pulmonary: dlco at least 50% of predicted other: no severe concomitant medical or psychiatric illnesses prior concurrent therapy: no extensive prior radiotherapy which would prevent administration of total body radiation patients may also participate in study mda-dm-92082 for retroviral gene marking of the autologous marrow and blood cells

Keywords: refractory chronic lymphocytic leukemia cyclophosphamide cytoxan neosar bone marrow transplantation total body irradiation chronic lymphocytic leukemia allogeneic autologous
bipolar sealer aquamantys use in total knee replacement

Conditions: Osteoarthritis; Arthritis; Surgery; Infection; Inflammation; Disability; Hemorrhage

Summary: this study will compare the clinical outcomes for patients undergoing a total knee replacement using a bipolar sealer, the aquamantys® system, as compared to standard electrocautery. total blood loss during the hospital stay and knee mobility and discharge factors will be analyzed.


Eligibility criteria:
inclusion criteria: * patient is ≥18 years of age * patient has failed conservative therapy of osteoarthritis of the knee and has been listed to undergo primary tka * patient is willing and able to provide written informed consent. * pre-assessment haemoglobin ≥ 11.0g/dl * patient is suitable to receive spinal anaesthesia with no peripheral nerve blocks * patients willing to undergo blood transfusion exclusion criteria: * patients that are listed for unicondylar or revision tka * patients who are being converted from a previous high tibial osteotomy and a previous unicondylar knee arthroplasty * fixed motor deficit thus affecting functional assessment of the knee * patients presenting with a non-osteoarthritis degenerative knee diagnosis * patients presenting with known contralateral knee osteoarthritis requiring simultaneous bilateral tka * patients presenting with a history of previous knee infection * patients presenting with a pre-operative knee range of motion \< 85° * knee deformity greater than 20 degrees varus or valgus * patients presenting with a history of bleeding disorders and/or are on chronic blood anticoagulation therapy * patients with significantly impaired renal function (defined by egfr \>30) * patients with allergy or sensitivity to non-steroidal anti-inflammatory drugs, ropivacaine, ketoprofen or adrenaline * patients presenting with an internal cardiac defibrillator * women who are pregnant * evidence of active (systemic or local) infection at time of surgery * patients who have habitual opioid use * patients who have a psychiatric or mental illness which could impair the consent process or ability to complete patient-report questionnaires * morbid obesity \[bmi \> 40\] * patients who are unwilling to undergo blood transfusion, if necessary * patients who are receiving any implant used in conjunction with a customised-cutting block system * any patient who cannot or will not provide written informed consent for participation in the study * those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems

Keywords: blood loss bipolar sealer aquamantys total knee replacement primary total knee arthroplasty
jc virus reactivation in multiple sclerosis

Conditions: Progressive Multifocal Leukoencephalopathy; Multiple Sclerosis

Summary: jc virus is a benign virus which infects approximately up to 90% of the normal adult population. however, it may be reactivated in people who have a decreased immune function as in hiv infection, cancer, chemotherapy, transplant recipients, or in ms patients treated with natalizumab (tysabri). in these patients, jc virus can cause a severe brain disease called progressive multifocal leukoencephalopathy (pml), for which there is no cure. as of september 2013, 400 ms patients in the world, who have been treated with natalizumab, have developed pml. the risk of pml is approximately 5 patients in 1000 after 24 months on the drug. researchers do not know exactly in which cells of the body the virus lives but it has been isolated from the blood, urine, cerebrospinal fluid (csf), and from the brains of patients with immunosuppression. in this study, the investigators wish to determine precisely where the virus lives, and how the body prevents it from causing brain disease. because of the association of pml with natalizumab, the investigators would like to see if there is a difference in the amounts of virus in blood, urine, and csf found in ms patients treated with natalizumab or those treated with different medications for ms, or those not treated at all. the investigators hope that this knowledge will allow us to find better ways of preventing the development of pml as well as treatments for patients with pml.

subjects selected for participation in this study have been diagnosed with multiple sclerosis (ms). of the ms patients enrolled in the study, some have been treated with natalizumab or a different medication for ms, and others have not been treated at all. all ms patients enrolled have their blood tested for the presence of the jc virus. those testing negative for the jc virus do not continue in the study. those testing positive for the jc virus continue participating in the study, and provide a urine sample, blood sample, lumbar puncture, and a neurological exam. approximately 65 people will take part in this study at beth israel deaconess medical center.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of multiple sclerosis, relapsing remitting exclusion criteria: * jcv sero-negative

Keywords: jc virus natalizumab